Evolus, Inc. Common Stock

EOLS

$4.11

Name : Evolus, Inc. Common Stock

Sector : Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Mark. Cap: $267,396,576.00

EPSttm : -0.8

Evolus, Inc. Common Stock

$4.11

4.31%

$0.17

EOLS — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

15.29

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

EPS Last/This Y

0.68

EPS This/Next Y

0.36

Price

4.11

Target Price

14.67

Analyst Recom

1.29

Performance Q

-38.29

Upside

-781.3%

Beta

Ticker: EOLS

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	EOLS	4.28	0.36	0.73	13316
2026-03-03	EOLS	4.12	0.37	1.75	13453
2026-03-04	EOLS	5.59	0.37	0.36	13625
2026-03-05	EOLS	5.67	0.39	0.34	14705
2026-03-06	EOLS	5.54	0.42	14.57	14683
2026-03-09	EOLS	5.36	0.42	2.09	14788
2026-03-10	EOLS	5.29	0.42	8.33	14763
2026-03-11	EOLS	5.39	0.42	999.99	14814
2026-03-12	EOLS	4.91	0.42	2.12	14811
2026-03-13	EOLS	4.91	0.42	1.96	14811
2026-03-17	EOLS	4.92	0.45	47.00	14964
2026-03-18	EOLS	4.84	0.46	0.43	15025
2026-03-19	EOLS	4.86	0.46	1.67	15040
2026-03-20	EOLS	4.64	0.46	0.02	15056
2026-03-23	EOLS	4.68	0.39	0.32	13618
2026-03-24	EOLS	4.44	0.39	0.95	13628
2026-03-25	EOLS	4.36	0.39	0.33	13634
2026-03-26	EOLS	4.18	0.39	1.36	13772
2026-03-27	EOLS	4.01	0.39	2.43	13798
2026-03-30	EOLS	3.94	0.40	0.75	13816
2026-03-31	EOLS	4.11	0.39	0.00	13754
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	EOLS	4.28	163.8	13.7	-0.39
2026-03-03	EOLS	4.12	163.8	14.2	-0.39
2026-03-04	EOLS	5.59	163.8	7.5	-0.39
2026-03-05	EOLS	5.67	163.8	13.3	-0.39
2026-03-06	EOLS	5.53	163.8	14.0	-0.39
2026-03-09	EOLS	5.37	30.9	21.7	-0.12
2026-03-10	EOLS	5.29	30.9	15.2	-0.12
2026-03-11	EOLS	5.39	30.9	14.8	-0.12
2026-03-12	EOLS	4.92	30.9	16.1	-0.12
2026-03-13	EOLS	5.02	30.9	14.7	-0.12
2026-03-17	EOLS	4.91	30.9	15.4	-0.12
2026-03-18	EOLS	4.84	30.9	15.2	-0.12
2026-03-19	EOLS	4.87	30.9	14.9	-0.12
2026-03-20	EOLS	4.64	30.9	15.6	-0.12
2026-03-23	EOLS	4.69	30.9	14.9	-0.12
2026-03-24	EOLS	4.43	30.9	15.7	-0.12
2026-03-25	EOLS	4.36	30.9	15.2	-0.12
2026-03-26	EOLS	4.18	30.9	15.5	-0.12
2026-03-27	EOLS	4.01	30.9	15.5	-0.12
2026-03-30	EOLS	3.95	30.9	15.2	-0.12
2026-03-31	EOLS	4.11	30.9	14.6	-0.12
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	EOLS	-0.07	-9.25	15.71
2026-03-03	EOLS	-0.08	-9.25	15.71
2026-03-04	EOLS	-0.08	-9.25	15.71
2026-03-05	EOLS	-0.08	-9.25	15.71
2026-03-06	EOLS	-0.08	-9.25	15.65
2026-03-09	EOLS	-0.08	-9.09	15.65
2026-03-10	EOLS	-0.08	-9.09	15.65
2026-03-11	EOLS	-0.08	-9.09	15.67
2026-03-12	EOLS	-0.08	-9.09	15.67
2026-03-13	EOLS	-0.08	-9.09	15.67
2026-03-17	EOLS	-0.08	-9.08	15.67
2026-03-18	EOLS	-0.08	-9.08	15.67
2026-03-19	EOLS	-1.04	-9.08	15.67
2026-03-20	EOLS	-1.04	-9.08	15.67
2026-03-23	EOLS	-1.14	-9.08	15.67
2026-03-24	EOLS	-1.14	-9.08	15.67
2026-03-25	EOLS	-1.14	-9.08	15.29
2026-03-26	EOLS	-1.14	-9.08	15.29
2026-03-27	EOLS	-1.14	-9.08	15.29
2026-03-30	EOLS	-1.14	-9.18	15.29
2026-03-31	EOLS	-1.14	-9.18	15.29
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.05

Insider Transactions

-1.14

Institutional Transactions

-9.18

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.9

Max Drawdown 5-Year %

-77.4

Target Price

14.67

P/E

Forward P/E

20.21

PEG

P/S

0.9

P/B

P/Free Cash Flow

EPS

-0.8

Average EPS Est. Cur. Y

-0.12

EPS Next Y. (Est.)

0.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-17.38

Relative Volume

0.61

Return on Equity vs Sector %

196.1

Return on Equity vs Industry %

216.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

14.6

◆ EOLS Healthcare

$4.11

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

17/25

Volume

9/15

Valuation

15/20

TP/AR

2/10

Options

8/10

RSI

37.2

Range 1M

11.1%

Sup Dist

5.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

25/30

Estimates

1/20

Inst/Vol

0/15

Options

6/10

EPS Yr

63.6%

EPS NY

227.1%

52W%

3.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +148% upside

Quality

7/30

Valuation

18/30

Growth

17/25

Stability

6/10

LT Trend

1/5

Upside

+148%

Quality

Evolus, Inc. Common Stock

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 334

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS

Latest News

—

Caricamento notizie per EOLS…

stock quote shares EOLS – Evolent Health Inc. Stock Price stock today

news today EOLS – Evolent Health Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EOLS – Evolent Health Inc. yahoo finance google finance

stock history EOLS – Evolent Health Inc. invest stock market

stock prices EOLS premarket after hours

ticker EOLS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: EOLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y